615 related articles for article (PubMed ID: 33245680)
21. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS.
Fan W; Guo J; Zhu B; Wang S; Yu L; Huang W; Fan H; Li F; Wu Y; Zhao Y; Wang Y; Xue M; Wang H; Li J
Eur Radiol; 2021 Nov; 31(11):8291-8301. PubMed ID: 33893536
[TBL] [Abstract][Full Text] [Related]
22. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
Gorodetski B; Chapiro J; Schernthaner R; Duran R; Lin M; Lee H; Lenis D; Stuart EA; Nonyane BA; Pekurovsky V; Tamrazi A; Gebauer B; Schlachter T; Pawlik TM; Geschwind JF
Eur Radiol; 2017 Feb; 27(2):526-535. PubMed ID: 27277261
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
[TBL] [Abstract][Full Text] [Related]
26. Comparison of CalliSpheres
Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
[TBL] [Abstract][Full Text] [Related]
27. Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma.
Razi M; Safiullah S; Gu J; He X; Razi M; Kong J
J Interv Med; 2022 Feb; 5(1):10-14. PubMed ID: 35586278
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis.
Zou JH; Zhang L; Ren ZG; Ye SL
J Dig Dis; 2016 Aug; 17(8):510-517. PubMed ID: 27384075
[TBL] [Abstract][Full Text] [Related]
29. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
30. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
33. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
[TBL] [Abstract][Full Text] [Related]
34. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
35. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
Chen J; Lai L; Zhou C; Luo J; Wang H; Li M; Huang M
Cancer Imaging; 2023 Jul; 23(1):70. PubMed ID: 37481660
[TBL] [Abstract][Full Text] [Related]
36. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
[TBL] [Abstract][Full Text] [Related]
37. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
[No Abstract] [Full Text] [Related]
38. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
[TBL] [Abstract][Full Text] [Related]
39. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
[TBL] [Abstract][Full Text] [Related]
40. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.
Li H; Liang C; Kuang D; Huang G; Zhang M; Chen P; Zheng Q; Xu W; Ren J; Han X; Duan X
Cancer Biol Ther; 2023 Dec; 24(1):2166335. PubMed ID: 36751709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]